Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Glioblastoma Clinical Trial

Official title:

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas: A Phase 0 Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04869449
• Other study ID #: STUDY00014115
• Status: Recruiting
• Phase: Early Phase 1
• Start date: May 12, 2022
• Est. completion date: January 2025

Study information

• Verified date: May 2024
• Source: Milton S. Hershey Medical Center
• Contact: Micaiah D Grien, BS
• Phone: 717-531-0003
• Email: mgrien[@]pennstatehealth.psu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

Description:

Both ketoconazole and posaconazole are FDA-approved anti-fungal agents with a well-established side effect and safety profile. Ketoconazole and posaconazole have shown efficacy in reducing tumor cell proliferation in in-vitro studies. Furthermore, both have also shown efficacy, mediated at least in part through inhibition of hexokinase 2 (HK2) activity, in animal models with dosing concentration and schedules that are documented as safe in humans. As a drug, posaconazole has a more predictable half-life than ketoconazole and has less off-target effects. Therefore, the proposed trial will focus on the role of posaconazole exclusively. As a first step, demonstration of adequate penetrance of study drug in brain and tumor tissue (pharmacokinetics) and biological effect (inhibition of glycolysis and subsequent tumor cell death) is necessary prior to large scale clinical studies. A total of 5 control participants will be included in this study as the investigator specifically wants to assess for pharmacodynamic differences too. The addition of a control group to this study rather to both the studies (ketoconazole study is a separate protocol) is because the investigator feels posaconazole may be a more promising drug for moving forward.

Plasma drug concentration measurements are an unreliable method to assess delivery of drugs across the blood-brain barrier. In contrast, intracerebral microdialysis catheters (MDC) monitoring allows for approximate measurements within extracellular fluid (ECF) sampling of the brain. MDC placement within the brain is not a novel technique and has been utilized routinely in the ICU setting to measure brain metabolism by sampling of ECF of traumatic brain injury patients.

MDC are now FDA-approved and are being placed routinely with intracranial pressure monitors. This method allows for continuous measurement of ECF within a tumor or normal tissue. The dialysis probe has a semipermeable membrane which is less than 1 mm in diameter into which two sections of microcatheter are fused. Previous studies have demonstrated the feasibility of keeping the catheters in place of critically injured patients for up to 2 weeks.

When placed at the time of surgical resection, the microcatheters are stereotactically implanted, placing the probe within the desired brain and/or tumor region. Externally, the catheter is connected to a syringe pump, which delivers a low flow rate (μl/min) of continuous perfusion fluid (Lactated Ringers or artificial CSF) and dialysate is collected in a microvial from the outlet tube. This sterile, single use catheter is minimally invasive and developed to achieve optimal diffusing characteristics similar to passive diffusion of a capillary blood vessel. Just as in the function of brain capillary vessel, water, inorganic ions and small organic molecules freely diffuse across the membrane of the probe, whereas proteins and protein bound compounds are impermeable. Additionally, lipophilic compounds are poorly recovered. Therefore, assessment of pharmacokinetics of drug using MDC provides valuable insight relevant to its anti-neoplastic properties.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years

• Evidence of primary or recurrent high-grade gliomas (HGG) that in the opinion of the treating team would require surgical resection

• Karnofsky Performance Score (KPS) = 60%

• Eastern Cooperative Oncology Group (ECOG) performance status = 2

• Life expectancy greater than 12 weeks

• Adequate liver function defined as Alanine aminotransferase (ALT),Aspartate transaminase (AST), Alkaline phosphatase (ALP) within 1.5x institutional upper limit of normal

• Adequate renal function defined as estimated glomerular filtration rate (eGFR) levels within 1.5x the institutional upper limit of normal

• Ability to swallow medication

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation.

• Ability to understand and willingness to sign a written informed consent document

• Be able to comply with treatment plan, study procedures and follow-up examinations

Exclusion Criteria:

• Patients may not be receiving any other investigational agents while on study

• Patients who have known allergy to ketoconazole or other azoles

• Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous azole class drugs for a parasitic infection

• Patients with a history of acute or chronic hepatitis

• Patients with liver enzymes (ALT, AST, ALP) >1.5x above normal range for the laboratory performing the test

• Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting ketoconazole therapy

• Patients who are taking any anti-convulsant medication that interferes with the cytochrome P450 pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.) and who cannot be switched to alternative medications such as keppra (levetiracetam)

• Uncontrolled intercurrent illness such as chronic hepatitis, acute hepatitis, or psychiatric illness/social situation that would limit compliance with study requirements

• Patients with a history of Addison's disease or other forms of adrenal insufficiency

• Patient with little or no stomach acid production (achlorhydria)

• Pregnant and breast feeding women

• Patients with a history of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product administration or may interfere with the interpretation of the results.

• Patients who are not available for follow-up assessments or unable to comply with study requirements.

• Patients who are currently taking medications that induce the metabolism of ketoconazole, such as isoniazid, nevirapine, rifamycins (such as rifabutin, rifampin), or St. John's wort and cannot be safely discontinued off of them for the duration of the trial.

• Patients who are currently taking medications for which the metabolism may be affected by ketoconazole, which include but are not limited to: benzodiazepines (such as alprazolam, midazolam, triazolam), domperidone, eletriptan, eplerenone, ergot drugs (such as ergotamine), nisoldipine, drugs used to treat erectile dysfunction (ED) or pulmonary hypertension (such as sildenafil, tadalafil), some drugs used to treat seizures (such as carbamazepine, phenytoin), some statin drugs (such as atorvastatin, lovastatin, simvastatin).

• Patients who are non-English speakers

• Patients who are not capable of understanding the consent form and would need a legally authorized representative.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme
• Glioblastoma Multiforme of Brain
• Glioblastoma Multiforme, Adult

Intervention

Drug:
• Ketoconazole
400 mg (two 200 mg tablets) orally

Locations

Country	Name	City	State
United States	Penn State Milton S Hershey Medical Center	Hershey	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Milton S. Hershey Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish drug concentration versus time profile yielding maximum plasma concentration (Cmax)	Assessment of the concentration versus time curves of drug in the dialysate fluid	Collected over a 24-hour period after surgery (biopsy or resection)
Primary	Establish drug concentration versus time profile yielding half-life pharmacodynamics	Assessment of the concentration versus time curves of drug in the dialysate fluid	Collected over a 24-hour period after surgery (biopsy or resection)
Secondary	Frequency and severity of treatment-emergent adverse events as assessed by CTCAE v 5.0	Measured through the Grade and Frequency of adverse events, based on the CTCAE v5.0 criteria	from Baseline to Visit 7 (14 days +/- 7 days post-op)
Secondary	Hexokinase activity assay- measured as a proportion of hexokinase enzyme activity in relation to positive control	Measured using a hexokinase assay on tumor tissue	Within 24 hours after tumor resection
Secondary	Concentration of lactate measured using mass spectrometry in resected tumor tissue	Measured using mass spectrometry	Immediately after biopsy or resection of tissue
Secondary	Concentration of pyruvate, measured using mass spectrometry in resected tumor tissue	Measured using mass spectrometry	Immediately after biopsy or resection of tissue
Secondary	Evaluate ketoconazole's effect on tumor proliferation in tumor tissue	Measured using Ki-67 proliferation index	Within 24 hours after biopsy or tumor resection
Secondary	Evaluate ketoconazole's effect on cell death in tumor tissue	Measured using TUNEL staining	Within 24 hours after biopsy or tumor resection
Secondary	Evaluate ketoconazole's effect on angiogenesis in tumor tissue	Based on expression of vascular endothelial growth factor (VEGF)	Within 24 hours after biopsy or tumor resection
Secondary	Correlation of concentration versus time profile of ketoconazole , compared to that of lactate - measured using mass spectrometry over 24 hours	Assessed based on the concentration versus time profile of lactate in the dialysate fluid	Over the same 24-hour period used to measure the concentration of drug
Secondary	Correlation of concentration versus time profile of ketoconazole, compared to that of pyruvate - measured using mass spectrometry over 24 hours	Assessed based on the concentration versus time profile of pyruvate in the dialysate fluid	Over the same 24-hour period used to measure the concentration of drug